Population-specific DPYD variants and fluoropyrimidine toxicity risk: an analysis using public genomic databases
Introduction: Fluoropyrimidines (FP), including 5-fluorouracil (5-FU) and capecitabine, are widely used chemotherapeutic agents. However, their toxicity varies significantly among patients, often because of genetic differences in DPYD, which encodes dihydropyrimidine dehydrogenase, an enzyme crucial...
Saved in:
| Main Authors: | Suvam Banerjee, Souvik Sengupta |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Clinical Medicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1470211825001617 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews
by: Sara Otero-Torres, et al.
Published: (2025-05-01) -
DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
by: Ana Hernández-Guío, et al.
Published: (2021-05-01) -
Identification of genetic markers associated with cisplatin-induced toxicity using public genomic databases
by: Suvam Banerjee
Published: (2025-07-01) -
P677: Implementation of pharmacogenomic DPYD-guided fluoropyrimidine dosing for cancer patients in Saskatchewan, Canada
by: Yanwei Xi, et al.
Published: (2025-01-01) -
Case report: A case of severe capecitabine toxicity due to confirmed in trans compound heterozygosity of a common and rare DPYD variant
by: Amy de Haar-Holleman, et al.
Published: (2024-09-01)